20 results found.
Shutting down the power in leukaemia stem cells
Leukaemia stem cells can be responsible for chronic myeloid leukaemia returning or developing resistance to treatment. Dr Vignir Helgason wants to find a way to destroy these stem cells, giving people the best possible chance of survival.
Zeroing in on a pathway that drives myeloma
Myeloma is a blood cancer of the plasma cells, which is difficult to treat. Professor Ulf Klein is studying a signalling pathway thought to be involved in the disease in the hope of being able to identify new treatment targets.
Mapping gene changes in ALL
A change in a gene called BCR-ABL can initiate the development of acute lymphoblastic leukaemia. However, other changes happen which cause the disease to develop fully. Dr Feldahn wants to understand more about this process.
Mapping the genetic changes in MPN
‘Atypical myeloproliferative neoplasms’ is the name given to a group of blood cancers that are rare and difficult to treat. Professor Nick Cross wants to understand more about how these diseases develop in the hope of finding new ways to treat them.
Developing a new type of treatment for leukaemia
Despite the progress we’ve made, we still not able to cure everyone with leukaemia with the treatments we have. Prof Terence Rabbitts is developing a brand-new type of treatment which could provide a new option for people with leukaemia.
Developing more effective and safer treatments for childhood leukaemia
We need to continue to develop treatments for childhood acute lymphoblastic leukaemia (ALL). Prof Tariq Enver and his team are learning more about the biology of childhood ALL, and why it sometimes comes back after treatment. This work could ensure that everyone gets treatments tailored for them, to give them the best chance of a cure.
The Precision Medicine in Aggressive Lymphoma consortium
Standard treatments for diffuse large B-cell lymphoma (DLBCL) don’t work for everyone. Prof Johnson is leading a team of researchers from across UK to find better ways to categorise and diagnose DLBCL. This will help ensure everyone with DLBCL gets the right treatment for them.
Understanding the biology of aggressive DLBCL
We need to find new ways to treat diffuse large B-cell lymphoma (DLBCL). Prof Ming-Qing Du is studying changes in the DNA of an aggressive type of DLBCL. This could lead to new treatments to give people living with the disease a better chance of survival.
Studying how the immune system behaves in myeloma
We need to find better ways to treat myeloma. Prof Kwee Yong is studying how the immune system changes in myeloma and during its treatment. She hopes that this could help people with myeloma keep their cancer at bay for longer.
Repurposing drugs to treat acute myeloid leukaemia
We desperately need new treatments for acute myeloid leukaemia (AML). Dr Karen Keeshan is studying whether existing drugs for solid tumours could be used to treat AML. This could quickly provide a new option for people living with the disease.
Studying the role of gene changes in acute myeloid leukaemia
We desperately need to find new treatments for acute myeloid leukaemia (AML). Prof Georges Lacaud is studying the role of a gene called MOZ. This could eventually lead to new treatments for this aggressive type of blood cancer.
Defining a group of aggressive diffuse large B-cell lymphomas
The treatments for diffuse large B-cell lymphoma (DLBCL) don’t always work for everyone with the disease. Prof David Westhead is defining a new subtype of aggressive DLBCL, which could lead to better treatments for people with this disease.
Using artificial intelligence to predict childhood leukaemia outcomes
Understanding the genetic causes of leukaemia would really help doctors diagnose and treat the disease more effectively, but interpreting genetic information can be very complicated. Dr Amir Enshaei and his team are using a technique called 'machine learning' to help identify the genetic changes that cause the disease
Improving the lives of children with leukaemia through tailored treatment
While we know that multiple genetic changes can cause leaukamia, it's hard to identify them without comparing lots of leukaemia DNA samples. Professor Christine Harrison's project collects and analyses genetic information from childeren with leukaemia to try and understand how to treat the disease.
Azacitidine is a drug given to be people with MDS but some people have to stop this treatment due to side effects. Dr Sternberg wants to find out whether combining azacitidine with another drug can stop this from happening.
It’s thought that combining the drug rituximab with a new drug called BI-1206 may prevent some types of non-Hodgkin lymphoma developing resistance to rituximab. In this trial, Dr Andrew Davies will begin this work to identify the safest dose of BI-1206 to give people.
The STELLAR trial: Finding new treatments for Richter’s syndrome
Richter’s syndrome is a complication of chronic lymphocytic leukaemia and is a condition very difficult to treat. In this trial, Dr Anna Schuh will add an additional drug to current treatment for Richter’s syndrome to see if this improves the outcome.
In this trial, researchers are looking at two drugs called azacitidine and vorinostat. They will see whether this treatment combinations works better than azacitidine alone for people with AML and MDS.
Before people with AML receive a donor stem cell transplant they have to have chemotherapy treatment called ‘conditioning treatment’ but this can cause severe side effects. In this trial, the team will try a new type of conditioning treatment to decrease side effects and reduce the chance of the disease returning.
Many people who have AML will be given the chemotherapy drug azacitidine. Professor Charles Craddock wants to see how well combining azacitidine with another drug works for people with AML.